LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・Becton Dickinson and Co

Becton Dickinson and Co

Suletud

SektorTervishoid

143.25 -0.84

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

142

Max

144.53

Põhinäitajad
By Trading Economics
Sissetulek	-692M -310M
Müük	-538M 4.7B
P/E Sektori keskmine	24.983 51.415
Aktsiakasum	2.9
Dividenditootlus	2.8
Kasumimarginaal	-6.576
Töötajad	60,000
EBITDA	-1B 189M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+26.12% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	2.80% 2.34%
Järgmine tulemuste avaldamine	6. aug 2026
Järgmine dividendimakse kuupäev	30. juuni 2026
Järgmine aktsia dividendi kuupäev (ex-date)	9. juuni 2026

Turustatistika
By TradingEconomics
Turukapital	-2.2B 39B
Eelmine avamishind	144.09
Eelmine sulgemishind	143.25

Uudiste sentiment

By Acuity

51%

49%

270 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

167 / 206.99 Toetus ja vastupanu

Becton Dickinson and Co Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. aug 2025, 11:19 UTC

Tulu

Becton Dickinson Boosts Outlook as 3Q Results Beat Estimates

14. juuli 2025, 14:26 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14. juuli 2025, 11:08 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14. juuli 2025, 10:37 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

7. aug 2025, 10:32 UTC

Tulu

Becton Dickinson Expects to Complete Remaining $250M of $1B Share-Buyback Commitment by End FY25 >BDX

7. aug 2025, 10:31 UTC

Tulu

Becton Dickinson Backs FY25 View of Rev $21.8B-$21.9B >BDX

7. aug 2025, 10:31 UTC

Tulu

Becton Dickinson Had Seen FY25 Adjusted EPS $14.06-$14.34 >BDX

7. aug 2025, 10:30 UTC

Tulu

Becton Dickinson Raises FY25 View To Adj EPS $14.30-Adj EPS $14.45 >BDX

7. aug 2025, 10:30 UTC

Tulu

Becton Dickinson 3Q Adj EPS $3.68 >BDX

7. aug 2025, 10:30 UTC

Tulu

Becton Dickinson 3Q Net $574M >BDX

7. aug 2025, 10:30 UTC

Tulu

Becton Dickinson 3Q Rev $5.51B >BDX

7. aug 2025, 10:30 UTC

Tulu

Becton Dickinson 3Q EPS $2.00 >BDX

15. juuli 2025, 18:32 UTC

Omandamised, ülevõtmised, äriostud

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15. juuli 2025, 18:31 UTC

Omandamised, ülevõtmised, äriostud

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14. juuli 2025, 16:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14. juuli 2025, 15:06 UTC

Omandamised, ülevõtmised, äriostud

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14. juuli 2025, 14:11 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14. juuli 2025, 10:53 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14. juuli 2025, 10:22 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14. juuli 2025, 10:22 UTC

Omandamised, ülevõtmised, äriostud

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14. juuli 2025, 10:22 UTC

Omandamised, ülevõtmised, äriostud

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14. juuli 2025, 10:21 UTC

Omandamised, ülevõtmised, äriostud

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14. juuli 2025, 10:20 UTC

Omandamised, ülevõtmised, äriostud

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14. juuli 2025, 10:19 UTC

Omandamised, ülevõtmised, äriostud

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14. juuli 2025, 10:19 UTC

Omandamised, ülevõtmised, äriostud

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14. juuli 2025, 10:18 UTC

Omandamised, ülevõtmised, äriostud

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14. juuli 2025, 10:18 UTC

Omandamised, ülevõtmised, äriostud

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14. juuli 2025, 10:17 UTC

Omandamised, ülevõtmised, äriostud

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14. juuli 2025, 10:16 UTC

Omandamised, ülevõtmised, äriostud

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14. juuli 2025, 10:16 UTC

Omandamised, ülevõtmised, äriostud

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

Võrdlus sarnastega

Hinnamuutus

Becton Dickinson and Co Prognoos

Hinnasiht

By TipRanks

26.12% tõus

12 kuu keskmine prognoos

Keskmine 182.2 USD 26.12%

Kõrge 221 USD

Madal 159 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Becton Dickinson and Co 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Becton Dickinson and Co aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

167 / 206.99Toetus ja vastupanu

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

270 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.